Inventor
WINQVIST OLA
SE30 patents
⚠️ This page may combine multiple inventors who share the name “WINQVIST OLA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ISR IMMUNE SYSTEM REGULATION HOLDING AB PUBL
8 patentsUS11304990B2Apr 19, 2022
Use of known compounds—intracellular infections
ISR IMMUNE SYSTEM REGULATION HOLDING AB PUBL0 citations58
US11059845B2Jul 13, 2021
Immune stimulating macrolides
ISR IMMUNE SYSTEM REGULATION HOLDING AB PUBL1 citations58
US11059844B2Jul 13, 2021
Immune stimulating macrolides
ISR IMMUNE SYSTEM REGULATION HOLDING AB PUBL1 citations58
US11059846B2Jul 13, 2021
Immune stimulating compound
ISR IMMUNE SYSTEM REGULATION HOLDING AB PUBL1 citations58
US10919927B2Feb 16, 2021
Immune stimulating macrolide
ISR IMMUNE SYSTEM REGULATION HOLDING AB PUBL0 citations58
US11672842B2Jun 13, 2023
Gonadotropin-releasing hormones for use as adjuvant immunotherapeutics
ISR IMMUNE SYSTEM REGULATION HOLDING AB PUBL0 citations51
US11564969B2Jan 31, 2023
Immunorhelin compounds for intracellular infections
ISR IMMUNE SYSTEM REGULATION HOLDING AB PUBL0 citations47
US11434258B2Sep 6, 2022
Compounds (immunorhelins)
ISR IMMUNE SYSTEM REGULATION HOLDING AB PUBL0 citations47
WINQVIST OLA
7 patentsUS8211425B2Jul 3, 2012
Method for treating disseminated cancer
WINQVIST OLA27 citations90
US8211424B2Jul 3, 2012
Method for treating malignant melanoma
WINQVIST OLA26 citations90
US8206702B2Jun 26, 2012
Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer
WINQVIST OLA31 citations90
US8709404B2Apr 29, 2014
Immunotherapy in cancer treatment
WINQVIST OLA5 citations68
US8877177B2Nov 4, 2014
Chemokine containing apheresis column and methods of use
WINQVIST OLA3 citations61
US8101173B2Jan 24, 2012
Method for treating urinary bladder cancer
WINQVIST OLA5 citations60
US8852581B2Oct 7, 2014
Treatment of inflammatory bowel disease
WINQVIST OLA1 citations46
TLA TARGETED IMMUNOTHERAPIES AB
7 patentsUS10429385B2Oct 1, 2019
Treating conditions associated with sepsis
TLA TARGETED IMMUNOTHERAPIES AB3 citations82
US10401357B2Sep 3, 2019
Treating cancer
TLA TARGETED IMMUNOTHERAPIES AB3 citations82
US9726666B2Aug 8, 2017
Diagnosing and treating inflammatory diseases
TLA TARGETED IMMUNOTHERAPIES AB2 citations71
US10502736B2Dec 10, 2019
Treating multiple sclerosis
TLA TARGETED IMMUNOTHERAPIES AB0 citations50
US10451620B2Oct 22, 2019
Treating conditions associated with metabolic syndrome
TLA TARGETED IMMUNOTHERAPIES AB0 citations50
US10422800B2Sep 24, 2019
Treating respiratory conditions
TLA TARGETED IMMUNOTHERAPIES AB0 citations50
US10408832B2Sep 10, 2019
Treating mental disorders
TLA TARGETED IMMUNOTHERAPIES AB0 citations50
SCRIPPS RESEARCH INST
4 patentsUS6355479B1Mar 12, 2002
MHC class II antigen-presenting systems and methods for activating CD4+ T cells
SCRIPPS RESEARCH INST98 citations98
US7402430B2Jul 22, 2008
MHC class II antigen-presenting systems and methods for activating CD4+ T cells
SCRIPPS RESEARCH INST1 citations62
US7074617B1Jul 11, 2006
MHC class II antigen-presenting systems and methods for activatind CD4+T cells
SCRIPPS RESEARCH INST1 citations62
US7439335B2Oct 21, 2008
MHC class II antigen-presenting systems and methods for activating CD4+ T cells
SCRIPPS RESEARCH INST0 citations51